IDH1 and cholangiocarcinoma: Ivosidenib (AG-120), is a targeted inhibitor of mutated IDH1 and its efficacy has been shown in a multicenter, randomized, double-blind, placebo-controlled, phase 3 study (CLarIDHy) including patients with previously treated, IDH1-mutant CCA.